Cargando…

Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity

The endocannabinoid system represents an integrated neuronal network involved in the control of several organisms’ functions, such as feeding behavior. A series of hybrids of 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (mimonabant), a well-known i...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimmito, Marilisa P., Stefanucci, Azzurra, Pieretti, Stefano, Minosi, Paola, Dvorácskó, Szabolcs, Tömböly, Csaba, Zengin, Gokhan, Mollica, Adriano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770484/
https://www.ncbi.nlm.nih.gov/pubmed/31527522
http://dx.doi.org/10.3390/biom9090492
_version_ 1783455483590344704
author Dimmito, Marilisa P.
Stefanucci, Azzurra
Pieretti, Stefano
Minosi, Paola
Dvorácskó, Szabolcs
Tömböly, Csaba
Zengin, Gokhan
Mollica, Adriano
author_facet Dimmito, Marilisa P.
Stefanucci, Azzurra
Pieretti, Stefano
Minosi, Paola
Dvorácskó, Szabolcs
Tömböly, Csaba
Zengin, Gokhan
Mollica, Adriano
author_sort Dimmito, Marilisa P.
collection PubMed
description The endocannabinoid system represents an integrated neuronal network involved in the control of several organisms’ functions, such as feeding behavior. A series of hybrids of 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (mimonabant), a well-known inverse agonist of the type-1 cannabinoid receptor (CB1), once used as an antiobesity drug, and the N-(2S)-substitutes of 1-[(4-fluorophenyl)methyl]indazole-3-carboxamide with 1-amino-3-methyl-1-oxobutane (AB-Fubinaca), 1-amino-3,3-dimethyl-1-oxobutane (ADB-Fubinaca), and 3-methylbutanoate (AMB-Fubinaca), endowed with potent agonistic activity towards cannabinoid receptors CB1 and CB2 were in solution as C-terminal amides, acids, methyl esters and N-methyl amides. These compounds have been studied by binding assays to cannabinoid receptors and by functional receptor assays, using rat brain membranes in vitro. The most active among them as an agonist, (S)-1-(2,4-dichlorobenzyl)-N-(3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (LONI11), and an antagonist, (S)-2-(1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoic acid (LONI4), were tested in vivo in mic, to evaluate their ability to stimulate or suppress feeding behavior after intraperitoneal (i.p.) administration. For a LONI11 formalin test and a tail flick test after an administration by the subcutaneous (s.c.) and intracerebroventricular (i.c.v.) routes, respectively, were also carried out in vivo in mice to investigate the antinociceptive property at the central and peripheral levesl. We observed a significant orexant effect for LONI11 and an intense anorexant effect for (S)-methyl 2-(1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (LONI2) and LONI4. In zymosan-induced edema and hyperalgesia, LONI11 reduced the percent of paw volume increase and paw latency after s.c. administration, also suggesting a possible peripheral anti-inflammatory activity.
format Online
Article
Text
id pubmed-6770484
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67704842019-10-30 Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity Dimmito, Marilisa P. Stefanucci, Azzurra Pieretti, Stefano Minosi, Paola Dvorácskó, Szabolcs Tömböly, Csaba Zengin, Gokhan Mollica, Adriano Biomolecules Article The endocannabinoid system represents an integrated neuronal network involved in the control of several organisms’ functions, such as feeding behavior. A series of hybrids of 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (mimonabant), a well-known inverse agonist of the type-1 cannabinoid receptor (CB1), once used as an antiobesity drug, and the N-(2S)-substitutes of 1-[(4-fluorophenyl)methyl]indazole-3-carboxamide with 1-amino-3-methyl-1-oxobutane (AB-Fubinaca), 1-amino-3,3-dimethyl-1-oxobutane (ADB-Fubinaca), and 3-methylbutanoate (AMB-Fubinaca), endowed with potent agonistic activity towards cannabinoid receptors CB1 and CB2 were in solution as C-terminal amides, acids, methyl esters and N-methyl amides. These compounds have been studied by binding assays to cannabinoid receptors and by functional receptor assays, using rat brain membranes in vitro. The most active among them as an agonist, (S)-1-(2,4-dichlorobenzyl)-N-(3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (LONI11), and an antagonist, (S)-2-(1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoic acid (LONI4), were tested in vivo in mic, to evaluate their ability to stimulate or suppress feeding behavior after intraperitoneal (i.p.) administration. For a LONI11 formalin test and a tail flick test after an administration by the subcutaneous (s.c.) and intracerebroventricular (i.c.v.) routes, respectively, were also carried out in vivo in mice to investigate the antinociceptive property at the central and peripheral levesl. We observed a significant orexant effect for LONI11 and an intense anorexant effect for (S)-methyl 2-(1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (LONI2) and LONI4. In zymosan-induced edema and hyperalgesia, LONI11 reduced the percent of paw volume increase and paw latency after s.c. administration, also suggesting a possible peripheral anti-inflammatory activity. MDPI 2019-09-16 /pmc/articles/PMC6770484/ /pubmed/31527522 http://dx.doi.org/10.3390/biom9090492 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dimmito, Marilisa P.
Stefanucci, Azzurra
Pieretti, Stefano
Minosi, Paola
Dvorácskó, Szabolcs
Tömböly, Csaba
Zengin, Gokhan
Mollica, Adriano
Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
title Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
title_full Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
title_fullStr Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
title_full_unstemmed Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
title_short Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
title_sort discovery of orexant and anorexant agents with indazole scaffold endowed with peripheral antiedema activity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770484/
https://www.ncbi.nlm.nih.gov/pubmed/31527522
http://dx.doi.org/10.3390/biom9090492
work_keys_str_mv AT dimmitomarilisap discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity
AT stefanucciazzurra discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity
AT pierettistefano discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity
AT minosipaola discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity
AT dvoracskoszabolcs discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity
AT tombolycsaba discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity
AT zengingokhan discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity
AT mollicaadriano discoveryoforexantandanorexantagentswithindazolescaffoldendowedwithperipheralantiedemaactivity